We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Companion Diagnostic Guides Colorectal Cancer Treatment

By LabMedica International staff writers
Posted on 18 Jul 2012
Print article
Image: Rotor-Gene Q MDx for the therascreen KRAS assay (Photo courtesy of Qiagen).
Image: Rotor-Gene Q MDx for the therascreen KRAS assay (Photo courtesy of Qiagen).
A companion diagnostic kit guides treatment for metastatic colorectal cancer patients for whom surgery and chemotherapy are insufficient.

The therascreen KRAS RGQ polymerase chain reaction (PCR) kit (therascreen KRAS test) provides guidance on the use of Erbitux (cetuximab, EGFR) as a treatment in patients with metastatic colorectal cancer. This companion diagnostic assay is used to determine the presence of mutations in the human KRAS gene that assist in identifying colorectal cancer patients most likely to benefit from anti-EGFR therapies.

The US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved the KRAS RGQ PCR Kit for use in the US. The manufacturer of the KRAS test kit, Qiagen (Hilden, Germany), already markets a broad range of companion diagnostic tests covering 30 biomarkers in Europe, Asia/Pacific and Japan.

In contrast to laboratory-developed tests (LDTs), the FDA-approved therascreen KRAS test gives healthcare providers a fast, consistent, and reliable process to determine optimal treatment for colorectal cancer patients who are candidates for EGFR-inhibitor therapy.

The therascreen KRAS test offers laboratories an efficient workflow based on the Rotor-Gene Q MDx, an automated molecular detection instrument that uses real-time PCR technology. All other companion diagnostics in development, as well as a range of other molecular diagnostic tests, are being developed for US regulatory approval on the Rotor-Gene Q MDx.

The therascreen KRAS kit is the second assay cleared/approved by the FDA for use on the Rotor-Gene Q MDx. Earlier in 2012, Qiagen's artus Infl A/B RG RT-PCR for the detection of Influenza A/B was cleared for use on Rotor-Gene Q MDx, with the instrument also receiving FDA 510(k) clearance at the same time.

Related Links:

US Food and Drug Administration
Qiagen


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.